Corpus ID: 12435883

[Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].

@article{Ristol1996DevelopmentAC,
  title={[Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].},
  author={P. Ristol and M. Gensana and J. Fern{\'a}ndez and M. Massot and P. Bhattacharya and J. Jorquera},
  journal={Sangre},
  year={1996},
  volume={41 2},
  pages={
          125-30
        }
}
AIM To develop a therapeutic human high purity FVIII concentrate, treated with two documented and complementary specific inactivation methods, for the treatment of haemophilia A. MATERIAL AND METHODS Cryoprecipitate was obtained from human plasma, normal for ALT levels and negative for HBsAg and antibodies to HIV and to HCV. The cryoprecipitate was resuspended and purified with PEG. The PEG precipitate was resuspended and treated with TNBP/Polysorbate 80. The mixture was processed by heparin… Expand
Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII